How much capital is needed to launch a Peptide Therapy Clinic?

You need a minimum of $746,000 cash, primarily covering $400,500 in initial capital expenditures like buildout and equipment, plus working capital until high utilization rates are achieved

What is the projected revenue growth for this clinic?

Revenue is projected to grow aggressively from $147 million in Year 1 (2026) to $927 million by Year 5 (2030), driven by scaling clinical staff from 6 to 17 FTEs

How long until the Peptide Therapy Clinic becomes profitable?

The financial model shows an operational breakeven in just 1 month, but the full payback period for the initial investment is projected to be 13 months, reflecting strong initial patient demand

What are the main variable costs in a Peptide Therapy Clinic?

Variable costs total about 215% of revenue, including 130% for Compounded Peptide Sourcing and Diagnostic Laboratory Fees, plus 85% for marketing and medical supplies

What is the expected return on investment (IRR)?

The projected Internal Rate of Return (IRR) is 152%, and the Return on Equity (ROE) is 1953%, indicating a solid return profile for investors in this specialized medical sector

How many clinical staff are needed to start the clinic?

The clinic starts with 6 clinical staff in 2026 (1 MD, 1 NP, 2 RNs, 1 Health Coach, 1 Phlebotomist) and plans to scale to 17 clinical staff by 2030 to meet demand

Peptide Therapy Clinic Business Plan: 7 Steps & $746K

How to Write a Business Plan for Peptide Therapy Clinic

Follow 7 practical steps to create a Peptide Therapy Clinic business plan in 10-15 pages, with a 5-year forecast (2026-2030), breakeven in 1 month, and funding needs near $746,000 clearly explained in numbers

How to Write a Business Plan for Peptide Therapy Clinic in 7 Steps

#	Step Name	Plan Section	Key Focus	Main Output/Deliverable
1	Define Service Model and Pricing Strategy	Concept	Set pricing tiers and confirm launch capital.	Finalized CAPEX requirement ($400,500).
2	Validate Demand and Capacity	Market	Confirm target volume assumptions based on demographics.	Projected initial monthly treatment mix (80 MD, 120 NP).
3	Map Clinical and Supply Chain	Operations	Detail supply sourcing and facility buildout costs.	Equipment budget ($75k) and COGS structure (85%/45%).
4	Structure the Organization and Talent Plan	Team	Define 11-person team structure and fixed wage load.	Annual fixed salary commitment ($565,000).
5	Develop Patient Acquisition Strategy	Marketing/Sales	Allocate acquisition spend and set utilization targets.	Digital marketing allocation (60%) and CLV plan.
6	Build the Core Financial Model	Financials	Model cash needs, breakeven, and 5-year growth.	$746k minimum cash and 1-month BE confirmation.
7	Identify Risks and Funding Needs	Risks	Assess regulatory hurdles and investor return timeline.	13-month payback period documented.

What is the regulatory landscape for compounded peptides in my target state?

The regulatory landscape for your Peptide Therapy Clinic hinges on state medical board definitions of scope of practice for NPs/RNs, coupled with the risk that the FDA could restrict compounded sourcing, which currently drives 85% of your Cost of Goods Sold (COGS). Before scaling, you need to map the exact rules in your target state to secure physician oversight and understand supply chain vulnerability; you can review general setup steps in How To Launch Peptide Therapy Clinic Business?

State Practice Authority

Confirm if the state medical board allows NPs to practice independently or requires physician oversight.
Check rules on telehealth prescribing for novel peptide protocols, which affects service delivery speed.
Verify the state's definition of compounding versus dispensing to gauge liability exposure.
If patient onboarding takes 14+ days, churn risk defintely rises due to long wait times.

Supply Chain Risk Assessment

Model the financial hit if the FDA restricts access to current compounding pharmacies.
Since 85% of COGS is tied to these sources, this is an existential threat to margins.
Research alternative, FDA-approved sourcing channels, even if they cost 30% more upfront.
Understand the difference between Section 503A and 503B compounding facility designations.

How quickly can we achieve the projected 50-60% clinical staff utilization rates?

Achieving the aggressive 1-month breakeven target for the Peptide Therapy Clinic requires utilization rates significantly higher than 30% immediately to cover the substantial fixed cost base. We must map the minimum monthly revenue needed to cover overhead before projecting success at the 50-60% utilization goal.

Modeling Low Utilization Risk

Annual fixed costs clock in at $805,000 ($565k salaries plus $240k overhead).
This means the monthly fixed cost floor is $67,083.
If utilization only hits 30%, the required revenue per treatment must be high to cover this gap.
We need to know the contribution margin to calculate the exact revenue required at 30%.

Breakeven Timeline Check

The assumption of a 1-month breakeven is highly optimistic for this model.
This timeline ignores the typical ramp-up period seen in specialized clinics, as explored in How Much Does A Peptide Therapy Clinic Owner Make?
To hit 50% utilization, patient volume must quickly surpass the minimum revenue needed to cover $67,083 monthly.
If onboarding takes 14+ days, churn risk rises, making the 1-month goal defintely harder to hit.

What is the definitive patient acquisition cost given the 60% marketing spend (Y1)?

The definitive Patient Acquisition Cost (PAC) is defintely uncalculatable right now because the required patient volume to support the $88.2 million marketing budget is missing, though treatment prices range from $125 to $850.

Marketing Budget & Volume

Year 1 marketing spend is budgeted at $88.2 million (60% of $147M revenue).
This massive spend must acquire enough patients to meet revenue targets.
We must map the flow: Consult leads to testing, then to ongoing treatment plans.
Review key performance indicators for clinic growth What Are The 5 KPIs For Peptide Therapy Clinic Business?.

Patient Value Levers

Average treatment price sits between $125 and $850 per session.
Customer Lifetime Value (CLV) hinges on how many refills a patient buys.
If the initial acquisition cost is too high, you need 5+ treatments just to break even on marketing.
Practitioner capacity limits how many new patients you can onboard monthly.

Can we secure and retain high-salaried clinical talent, especially the Medical Director ($285,000)?

Securing your $285,000 Medical Director requires benchmarking total compensation against specialized wellness providers, while contingency planning must address immediate coverage gaps to protect patient continuity, something you need to model closely against your fee-for-service revenue structure, detailed further in What Are Peptide Therapy Clinic Operating Costs?

Define Clinical Pay Structure

Medical Director base salary is set at $285,000.
Benchmark NP and RN pay against local US metropolitan averages.
Consider structuring a portion of MD pay based on protocol adherence.
High-value patient base supports premium clinical overhead costs.

Plan for Turnover Risk

Develop a formal contingency plan for MD absence.
Identify qualified NPs who can manage patient loads immediately.
If onboarding takes 14+ days, churn risk rises defintely.
Retention hinges on offering autonomy in data-driven protocol design.

Key Takeaways

This business plan necessitates $746,000 in total funding to cover $400,500 in initial CAPEX, targeting an aggressive operational breakeven point within just one month.
The financial model projects exponential revenue growth, scaling from $147 million in Year 1 (2026) to $927 million by the end of Year 5 (2030).
Key operational challenges involve managing high variable costs, including 130% allocated to peptide sourcing and lab fees, and validating the 60% initial marketing spend required for patient volume.
Successful execution depends heavily on securing specialized clinical talent, such as the $285,000 Medical Director, while navigating complex state-specific regulatory frameworks for compounded peptides.

Step 1 : Define Service Model and Pricing Strategy

Service Tiers Set Value

Defining your service tiers sets the entire revenue capture mechanism for this clinic. You must lock down core peptide protocols before setting prices, as this determines the complexity of the service. This establishes your fee hierarchy: MD treatments start at $850, while RN treatments begin at $250. This differential reflects liability and expertise. Get this wrong, and capacity planning fails.

Budget Confirmation

Before you market anything, confirm the total $400,500 CAPEX budget needed for launch. This capital covers initial build-out and working cash flow until you hit breakeven. Use the $850 and $250 starting prices to stress-test how quickly you can service this investment. Anyway, if protocol documentation takes too long, your launch timeline slips.

Step 2 : Validate Demand and Capacity

Confirm Volume Feasibility

You must lock down patient throughput before spending the $400,500 CAPEX budget. If the affluent market in your metro area can't support 80 MD treatments and 120 NP treatments monthly, your aggressive 1-month operational breakeven point fails instantly. This step tests if your assumed revenue pipeline matches the physical capacity you plan to build. Honestly, if you can't prove demand exists for these specific service mixes, you're just building an expensive waiting room.

Map Target Density

To validate the 200 total monthly treatments, map the density of your target demographic-affluent residents aged 35 to 65-within a 5-mile radius of the planned clinic location. If your target zip code only has 500 such households, capturing 40% of them for monthly visits is unrealistic. Use local wealth data to calculate the Total Addressable Market (TAM) for high-end wellness services. If you need the projected $746,000 in minimum cash, you need defintely proof that these volumes are achievable quickly. If onboarding takes 14+ days, churn risk rises.

Step 3 : Map Clinical and Supply Chain

Supply Chain Control

Controlling supply chain is vital because 85% of revenue rides on compounded peptides. If sourcing fails, the entire revenue stream stops dead. You need vetted compounding pharmacies that meet strict quality standards. This step locks in your cost of goods sold and ensures product consistency for personalized protocols. Poor sourcing means unhappy, non-compliant clients.

Sourcing Actions

Establish dual sourcing for peptides to mitigate single-point failure. For diagnostic lab fees, which account for 45% of revenue, negotiate preferred pricing tiers based on projected volume. Allocate $75,000 of the capital expenditure budget specifically for essential clinic equipment and layout setup. It's defintely a balancing act.

Step 4 : Structure the Organization and Talent Plan

Team Foundation

Getting the initial structure right defines your immediate operating leverage. You need 11 full-time employees (FTEs) ready to go before seeing significant revenue. This core team includes 1 Medical Director (MD), 1 Nurse Practitioner (NP), 2 Registered Nurses (RNs), and 5 administrative/management FTEs. These roles support the revenue generation planned from practitioner capacity.

The fixed cost for these initial salaries is $565,000 annually. This number hits your Profit & Loss statement immediately, so ensure these hires are productive from day one. You can't afford idle time when fixed overhead is this high. It's a big fixed commitment.

Projecting Clinical Hires

You must map out clinical staffing needs all the way to 2030. This isn't just a headcount exercise; it's managing future variable capacity against fixed overhead. If you hit the aggressive growth targets projected in the model, you'll need to hire ahead of demand spikes.

For example, if NP treatments grow by 20% year-over-year after launch, you need a hiring pipeline ready six months before the current NP hits 90% utilization. Defintely plan for RN hiring cycles to be longer than admin replacements. Consider that the 2 RNs are your primary volume drivers after the MD and NP see initial patients.

Step 5 : Develop Patient Acquisition Strategy

Acquisition Engine

Spending 60% of your budget on digital marketing is how you fill the chairs booked by your 1 MD and 1 NP. This spend must directly translate into booked appointments since revenue hinges on practitioner capacity. If lead quality is poor, you waste cash fast. This is the primary lever for achieving volume targets early on.

The main challenge here is attribution. You must defintely know which digital channel drives the high-value $850 MD visits versus the $250 RN follow-ups. Without tight tracking, optimizing that 60% spend becomes guesswork, delaying profitability.

Measuring Success

Set clear Key Performance Indicators (KPIs) based on capacity. Start tracking utilization rate-the percentage of available appointment slots filled-aiming for 40-60% in the first few months. Hitting 60% utilization proves your marketing spend is working efficiently.

Next, focus on retention to maximize Customer Lifetime Value (CLV), which is the total expected revenue from one patient relationship. Design onboarding flows that immediately push patients toward their next scheduled MD treatment to secure long-term revenue streams.

Step 6 : Build the Core Financial Model

Model Validation Check

This financial model is where you test the ambition against reality; it proves if your scaling assumptions actually fund the operation. You must confirm the required $746,000 minimum cash covers the initial negative cash flow until you hit targets. The projections show aggressive growth, moving revenue from $147 million in Year 1 up to $927 million by Year 5. That pace requires flawless execution from day one.

The most critical metric here is the operational breakeven point, which is set aggressively at just 1 month. Given the high fixed costs tied to your 11-person team structure and salaries totaling $565,000, this timeline is extremely tight. You're betting that patient utilization rates immediately hit the 40-60% range mentioned in the acquisition plan.

Hitting the 1-Month Breakeven

To achieve a 1-month breakeven, you must immediately convert marketing spend into high-value services. Since revenue depends on practitioner capacity, you need to ensure the MD treatments (starting at $850) and RN treatments (starting at $250) are booked solid within the first 30 days. This rapid volume must offset the high fixed wage burden.

What this estimate hides is the lag time in supply chain setup. The model assumes you secure all necessary compounded peptides (which make up 85% of revenue costs) without delay. If securing initial inventory or regulatory approvals pushes the launch past the planned date, that 1-month breakeven shifts, burning through your $746,000 runway much faster.

Step 7 : Identify Risks and Funding Needs

Risk & Spend Lock

Founders must face regulatory hurdles before spending capital. Peptide therapy operates in a gray area regarding Food and Drug Administration oversight, meaning compliance costs can spike fast. This step locks down the initial investment needed to open the doors, which is $400,500 in CAPEX. If you skip this, you risk building a model on shaky legal ground.

You need clear legal counsel now to map out compliance pathways for compounding sourcing and patient protocols. This assessment directly informs how much runway you need. Honestly, ignoring compliance risks is the fastest way to burn through your initial funding before seeing a single patient.

Payback Certainty

Focus on the investor timeline now that you have the hard numbers. The model projects a 13-month payback period for initial capital deployment. This means investors see a return start happening near the end of year one. Make sure your cash flow projections support this aggressive timeline.

The required $400,500 CAPEX must be secured before starting operations, as it covers essential setup costs mentioned in Step 1. If regulatory delays push launch past Q3 2025, that 13-month payback slips quickly. We need to defintely model a 3-month regulatory buffer.